SEC Form 4 · accession 0001209191-17-016741
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederick W Driscoll
Officer — Chief Financial Officer
Period of report
Feb 28, 2017
Accepted (ET)
Mar 2, 2017 · 4:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2017 | M | 30,000 | $7.8861 | A | 41,211 | D | |
| Common StockF3 | Feb 28, 2017 | S | 32,834 | $19.9619 | D | 8,377 | D | |
| Common StockF4 | Feb 28, 2017 | S | 600 | $20.4167 | D | 7,777 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F5 | $7.8861 | Feb 28, 2017 | M | 30,000 | D | — | May 19, 2023 | Common Stock | 30,000 | 105,300 | D |
Explanation of responses
- F1Includes 680 shares of Common Stock that were acquired by the Reporting Person on November 20, 2015 pursuant to the Issuer's Employee Stock Purchase Plan.
- F2Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 20, 2016.
- F3The weighted average sale price for the transaction reported was $19.9619, and the range of prices were between $19.41 and $20.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4The weighted average sale price for the transaction reported was $20.4167, and the range of prices were between $20.41 and $20.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F51/4 of the shares subject to the option vest one year after May 20, 2013, with 1/48th of the shares vesting monthly thereafter over the next 3 years.